Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14136MR)

This product GTTS-WQ14136MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Atherosclerosis&Acute coronary syndrome (ACS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14136MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13938MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ8171MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ12887MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ13595MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ12555MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NV-01
GTTS-WQ5382MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ11181MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ11860MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-7684
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW